ストックスクリーナーアプリを入手
0.6139
10.09%
-0.0689
アフターアワーズ：
.66
0.0461
+7.51%
前日終値:
$0.6828
開ける：
$0.6896
24時間の取引高:
494.82K
Relative Volume:
0.83
時価総額：
$55.28M
収益：
$2.24M
当期純損益:
$-136.67M
株価収益率:
-0.2681
EPS:
-2.29
ネットキャッシュフロー:
$-102.08M
1週間 パフォーマンス:
-13.81%
1か月 パフォーマンス:
-21.30%
6か月 パフォーマンス:
-62.57%
1年 パフォーマンス:
-84.50%
1日の値動き範囲:
$0.6021
$0.6922
1週間の範囲:
$0.6021
$0.73
52週間の値動き範囲:
$0.6021
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
名前
Century Therapeutics Inc
セクター
電話
215-981-4000
住所
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
IPSC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.6139 | 55.28M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-08 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 開始されました | Chardan Capital Markets | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-05-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-12 | 開始されました | William Blair | Mkt Perform |
| 2021-07-13 | 開始されました | BofA Securities | Buy |
| 2021-07-13 | 開始されました | JP Morgan | Overweight |
| 2021-07-13 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Century Therapeutics Inc (IPSC) 最新ニュース
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
Century Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Century Therapeutics faces Nasdaq delisting over share price - Investing.com
Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at 04:20 pm EST - Marketscreener.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Century Therapeutics CEO sells shares worth $27,179 - Investing.com
Century Therapeutics CEO sells shares worth $27,179 By Investing.com - Investing.com UK
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World
Leerink Partnrs Has Strong Forecast for IPSC FY2024 Earnings - Defense World
Brokers Offer Predictions for IPSC FY2029 Earnings - Defense World
FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs - MarketBeat
Ratios Reveal: Breaking Down Century Therapeutics Inc (IPSC)’s Financial Health - The Dwinnex
Quarterly Snapshot: Quick and Current Ratios for Janux Therapeutics Inc (JANX) - The Dwinnex
Analyzing Telephone And Data Systems, Inc (TDS) After Recent Trading Activity - Knox Daily
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Century Therapeutics COO Farid Adrienne sells $822 in stock - MSN
Century Therapeutics SVP sells shares worth $273 to cover taxes - MSN
Century Therapeutics COO Farid Adrienne sells $822 in stock By Investing.com - Investing.com Canada
Century Therapeutics SVP sells shares worth $273 to cover taxes By Investing.com - Investing.com Canada
Financial Metrics Exploration: Understanding Century Therapeutics Inc (IPSC) Through Ratios - The Dwinnex
JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MyChesCo
Century Therapeutics Inc (IPSC) 財務データ
収益
当期純利益
現金流量
EPS
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):